A Phase II trial miss is usually nothing to shout about, but Actelion Pharmaceuticals Ltd. put an optimistic gloss on macitentan's failure to demonstrate efficacy in idiopathic pulmonary fibrosis (IPF), emphasizing its favorable safety profile, which could augur well for an ongoing Phase III trial in pulmonary arterial hypertension (PAH).